Epogen, Procrit, Retacrit

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ Same as Referring Provider ❑ Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical*	❑ *Home*	❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital*	❑ *Office*	❑ *Pharmacy*

What is the ICD-10 code? _____

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 CareFirst MR C26704-A Epogen, Procrit, Retacrit SGM 1619-A – 04/2025.

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com

Exception Criteria Questions:

A. What is the prescribed product?

❒ Epogen, *Continue to Question B*

❒ Procrit, *Skip to Clinical Criteria Questions*

❒ Retacrit, *Skip to Clinical Criteria Questions*

B. The preferred products for your patient's health plan are Aranesp, Procrit, and Retacrit. Can the patient's treatment be switched to one of the preferred products?

❒ Yes, Aranesp, *Please obtain Form for preferred product and submit for corresponding PA*

❒ Yes, Procrit, *Skip to Clinical Criteria Questions.*

❒ Yes, Retacrit, *Skip to Clinical Criteria Questions*

❒ No, *Continue to Question C*

C. Does the patient have a documented intolerable adverse event to the preferred product Retacrit and Procrit? ***ACTION REQUIRED****: If Yes, attach supporting chart note(s)*

❒ Yes, *Continue to Question D*

❒ No, *Continue to Question D*

D. Was the documented intolerable adverse event an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products)? ***ACTION REQUIRED****: If No, attach supporting chart note(s)*

❒ Yes, *Continue to Question E*

❒ No, *Continue to Question E*

E. Is the product being requested for the treatment of anemia due to chronic kidney disease (CKD) or anemia due to myelosuppressive chemotherapy in cancer?

❒ Yes, *Continue to Question F*

❒ No, *Skip to Clinical Criteria Questions*

F. Does the patient have a documented inadequate response or intolerable adverse event to the preferred product Aranesp? ***ACTION REQUIRED****: If Yes, attach supporting chart note(s)*

❒ Yes, *Continue to Clinical Criteria Questions*

❒ No, *Continue to Clinical Criteria Questions*

Clinical Criteria Questions:

Which drug is being prescribed? ❑ Epogen ❑ Procrit ❑ Retacrit ❑ Other _____

1. What is the diagnosis?

❒ Anemia due to chronic kidney disease (CKD), *Continue to 2*

❒ Anemia due to myelosuppressive chemotherapy, *Continue to 2*

❒ Anemia in myelodysplastic syndrome (MDS), *Continue to 2*

❒ Presurgical use to reduce allogeneic blood transfusions, *Continue to 29*

❒ Anemia due to zidovudine treatment in a patient with human immunodeficiency virus (HIV) infection, *Continue to 2*

❒ Anemia in patients who will not/cannot receive blood transfusions (e.g., religious beliefs), *Continue to 2*

❒ Myelofibrosis-associated anemia, *Continue to 2*

❒ Anemia due to cancer, *Continue to 2*

❒ Other, please specify. _____, *No further questions*

2. Will the requested medication be used concomitantly with other erythropoiesis stimulating agents (ESAs)?

❒ Yes, *Continue to 3*

❒ No, *Continue to 3*

3. Has the patient received erythropoiesis stimulating agent (ESA) therapy in the previous month (within 30 days of request)?

❒ Yes, *Continue to 4*

❒ No, *Continue to 19*

4. Has the patient completed at least 12 weeks of erythropoiesis stimulating agent (ESA) therapy? Indicate therapy start date and number of weeks completed. _____

❒ Yes, *Continue to 6*

❒ No, *Continue to 5*

5. At any time since the patient started ESA therapy, has the patient's hemoglobin (Hgb) increased by 1 g/dL or more?

❒ Yes, *Continue to 7*

❒ No, *No Further Questions*

6. At any time since the patient started ESA therapy, has the patient's hemoglobin (Hgb) increased by 1 g/dL or more?

❒ Yes, *Continue to 7*

❒ No, *Continue to 7*

7. Has the patient been assessed for iron deficiency anemia?

❒ Yes, *Continue to 8*

❒ No, *Continue to 8*

8. What is the most recent serum transferrin saturation (TSAT) level? Indicate percentage.

❒ Less than 20% _____%, *Continue to 10*

❒ Greater than or equal to 20% _____%, *Continue to 9*

❒ Unknown, *Continue to 10*

9. Was the most recent serum transferrin saturation (TSAT) level obtained within the prior 3 months? Indicate date lab was drawn. _____ MM/DD/YYYY
❒ Yes, *Continue to 11*
❒ No, *Continue to 10*

10. Is the patient receiving iron therapy?
❒ Yes, *Continue to 11*
❒ No, *Continue to 11*

11. What is the diagnosis?

❒ Anemia due to chronic kidney disease (CKD), *Continue to 16*

❒ Anemia due to myelosuppressive chemotherapy, *Continue to 12*

❒ Anemia in myelodysplastic syndrome (MDS), *Continue to 16*

❒ Anemia in patients who will not/cannot receive blood transfusions (e.g., religious beliefs), *Continue to 16*
❒ Anemia due to zidovudine treatment in a patient with human immunodeficiency virus (HIV) infection, *Continue to 13*

❒ Myelofibrosis-associated anemia, *Continue to 16*

❒ Anemia due to cancer, *Continue to 18*

12. Does the patient have a non-myeloid malignancy?
❒ Yes, *Continue to 16*
❒ No, *Continue to 16*

13. Is the patient currently receiving a zidovudine-containing medication?
❒ Yes, *Continue to 14*
❒ No, *Continue to 14*

14. What is the patient's current hemoglobin (Hgb) level (exclude values due to a recent transfusion)?

❒ Less than 12 g/dL, *Continue to 15*

❒ Greater than or equal to 12 g/dL, *Continue to 15*

❒ Unknown, *Continue to 15*

15. Was the patient's current hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.

❒ Yes _____ MM/DD/YYYY, *No further questions*

❒ No _____ MM/DD/YYYY, *No further questions*

❒ Unknown, *No further questions*

16. What is the patient's current hemoglobin (Hgb) level (exclude values due to a recent transfusion)?

❒ Less than 12 g/dL, *Continue to 17*

❒ Greater than or equal to12 g/dL, *Continue to 17*

❒ Unknown, *Continue to 17*

17. Was the patient's current hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.

❒ Yes _____ MM/DD/YYYY, *No further questions*

❒ No _____ MM/DD/YYYY, *No further questions*

❒ Unknown, *No further questions*

18. Is the patient undergoing palliative treatment?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

19. Has the patient been assessed for iron deficiency anemia?
❒ Yes, *Continue to 20*
❒ No, *Continue to 20*

20. What is the most recent serum transferrin saturation (TSAT) level? Indicate percentage.

❒ Less than 20 % _____%, *Continue to 22*

❒ Greater than or equal to 20% _____%, *Continue to 21*

❒ Unknown, *Continue to 22*

21. Was the most recent serum transferrin saturation (TSAT) level obtained within the prior 3 months? Indicate date lab was drawn. _____ MM/DD/YYYY
❒ Yes, *Continue to 23*
❒ No, *Continue to 22*

22. Is the patient receiving iron therapy?
❒ Yes, *Continue to 23*
❒ No, *Continue to 23*

23. What is the diagnosis?

❒ Anemia in chronic kidney disease (CKD), *Continue to 26*

❒ Anemia due to myelosuppressive chemotherapy, *Continue to 24*

❒ Anemia in myelodysplastic syndrome (MDS), *Continue to 26*
❒ Anemia due to zidovudine treatment in a patient with human immunodeficiency virus (HIV) infection, *Continue to 37*

❒ Anemia in patients who will not/cannot receive blood transfusions (e.g., religious beliefs), *Continue to 26*

❒ Myelofibrosis-associated anemia, *Continue to 25*

❒ Anemia due to cancer, *Continue to 28*

24. Does the patient have a non-myeloid malignancy?
❒ Yes, *Continue to 26*
❒ No, *Continue to 26*

25. What is the patient's pretreatment serum erythropoietin (EPO) level?

❒ Less than 500 mU/mL, *Continue to 26*

❒ Greater than or equal to 500 mU/mL, *Continue to 26*

❒ Unknown, *Continue to 26*

26. What is the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion)?

❒ Less than 10 g/dL, *Continue to 27*

❒ Greater than or equal to 10 g/dL, *Continue to 27*

❒ Unknown, *Continue to 27*

27. Was the patient's pretreatment hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.

❒ Yes _____ MM/DD/YYYY, *No further questions*

❒ No _____ MM/DD/YYYY, *No further questions*

❒ Unknown, *No further questions*

28. Is the patient undergoing palliative treatment?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

29. Will the requested drug be used concomitantly with other erythropoiesis stimulating agents (ESAs)?
❒ Yes, *Continue to 30*
❒ No, *Continue to 30*

30. Has the patient been assessed for iron deficiency anemia?
❒ Yes, *Continue to 31*
❒ No, *Continue to 31*

31. What is the most recent serum transferrin saturation (TSAT) level? Indicate percentage.

❒ Less than 20% _____%, *Continue to 33*

❒ Greater than or equal to 20% _____%, *Continue to 32*

❒ Unknown, *Continue to 33*

32. Was the most recent serum transferrin saturation (TSAT) level obtained within the prior 3 months? Indicate date lab was drawn. _____ MM/DD/YYYY
❒ Yes, *Continue to 34*
❒ No, *Continue to 33*

33. Is the patient receiving iron therapy?
❒ Yes, *Continue to 34*
❒ No, *Continue to 34*

34. Is the patient scheduled to have an elective, noncardiac, nonvascular surgery?

❒ Yes, *Continue to 35*
❒ No, *Continue to 35*

35. What is the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion)?

❒ Less than or equal to 13 g/dL, *Continue to 36*

❒ Greater than 13 g/dL, *Continue to 36*

❒ Unknown, *Continue to 36*

36. Was the patient's pretreatment hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.

❒ Yes _____ MM/DD/YYYY, *No further questions*

❒ No _____ MM/DD/YYYY, *No further questions*

❒ Unknown, *No further questions*

37. Is the patient currently receiving treatment with a zidovudine-containing medication?
❒ Yes, *Continue to 38*
❒ No, *Continue to 38*

38. What is the patient's pretreatment serum erythropoietin (EPO) level?

❒ Less than or equal to 500 mU/mL, *Continue to 39*

❒ Greater than 500 mU/mL, *Continue to 39*

❒ Unknown, *Continue to 39*

39. What is the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion)?

❒ Less than 10 g/dL, *No further questions*

❒ Greater than or equal to 10 g/dL, *No further questions*

❒ Unknown, *No further questions*

Step Therapy Override: Complete if Applicable for the state of Maryland.	Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?	Yes	No
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?	Yes	No
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?	Yes	No
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?	Yes	No

Step Therapy Override: Complete if Applicable for the state of Virginia.	Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No
Is the preferred drug contraindicated?	Yes	No
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720